TWIST1-Induced miR-424 Reversibly Drives Mesenchymal Programming while Inhibiting Tumor Initiation.
Authors: Drasin D, Guarnieri A, Neelakantan D, Kim J, Cabrera J, Wang C, Zaberezhnyy V, Gasparini P, Cascione L, Huebner K, Tan A, Ford H
Cancer Res, 2015;75(9):1908-21.
Species: Human
Sample Type: Whole Cells
Application: Flow
Molecular signatures and transcriptional regulatory networks of human immature decidual NK and mature peripheral NK cells.
Authors: Wang F, Zhou Y, Fu B, Wu Y, Zhang R, Sun R, Tian Z, Wei H
Eur J Immunol, 2014;44(9):2771-84.
Species: Human
Sample Type: Whole Cells
Application: Flow
Expression of growth factors and growth factor receptor in non-healing and healing ischaemic ulceration.
Authors: Murphy MO, Ghosh J, Fulford P, Khwaja N, Halka AT, Carter A, Turner NJ, Walker MG
Eur J Vasc Endovasc Surg, 2006;31(5):516-22.
Species: Human
Sample Type: Whole Tissue
Application: IHC
Inhibin alpha-subunit and the inhibin coreceptor betaglycan are downregulated in endometrial carcinoma.
Authors: Florio P, Ciarmela P, Reis FM, Toti P, Galleri L, Santopietro R, Tiso E, Tosi P, Petraglia F
Eur. J. Endocrinol., 2005;152(2):277-84.
Species: Human
Sample Type: Whole Tissue
Application: IHC Paraffin-embedded
Extracellular domain of TGFbeta type III receptor inhibits angiogenesis and tumor growth in human cancer cells.
Authors: Bandyopadhyay A, Zhu Y, Malik SN, Kreisberg J, Brattain MG, Sprague EA, Luo J, Lopez-Casillas F, Sun LZ
Oncogene, 2002;21(22):3541-51.
Species: Human
Sample Type: Cell Culture Supernates
Application: ELISA Development
TGF-beta1 regulates TGF-beta1 and FGF-2 mRNA expression during fibroblast wound healing.
Authors: Song QH, Klepeis VE, Trinkaus-Randall V
MP, Mol. Pathol., 2002;55(3):164-76.
Species: Rabbit
Sample Type: Whole Tissue
Application: IHC
Transforming growth factor-beta1 regulation of growth zone chondrocytes is mediated by multiple interacting pathways.
Authors: Rosado E, Schwartz Z, Sylvia VL, Dean DD, Boyan BD
Biochim. Biophys. Acta, 2002;1590(1):1-15.
Species: Rat
Sample Type: Whole Cells
Application: Neut

Most cell types express three sizes of receptors for TGF-beta. These are designated Type I (53 kDa), Type II (70-85 kDa), and Type III (250-350 kDa). The Type I receptor is a membrane-bound serine/threonine kinase that apparently requires the presence of the Type II receptor to bind TGF-beta. The Type II receptor is also a membrane-bound serine/threonine kinase that binds TGF-beta 1 and TGF-beta 3 with high affinity and TGF-beta 2 with a much lower affinity. The Type I and Type II receptors together form a heterodimeric signaling complex that is essential for the transduction of the anti-proliferative signals of TGF-beta.

The Type III receptor is a transmembrane proteoglycan with a large extracellular domain and a 43 amino acid residue cytoplasmic domain. The cytoplasmic domain of the Type III receptor lacks an obvious signaling motif and the receptor may not be involved directly in signal transduction. The Type III receptor binds TGF-beta 2 with the highest affinity. Other TGF-beta isoforms also bind the Type III receptor, but with lower affinities. Cellular responsiveness to TGF-beta 2 appears to be dependent on the presence of the Type III receptor which can interact with the signaling receptor complex. In addition to the transmembrane Type III receptor, a soluble form of the receptor is secreted by some cell types. The physiological role of this soluble receptor remains to be determined. The recombinant TGF-beta soluble receptor Type III binds the TGF-beta isoforms differentially in solution and exhibits TGF-beta antagonistic activities in vitro.

• Airway Inflammation and Remodeling
• Cytokines and Receptors in Allergy and Asthma
• Cytokines and Receptors in Angiogenesis
• Proteoglycans
• T Cell Cytokine Signaling
• TGF-beta Family
• TGF-beta Superfamily